Flow cytometry was first used to isolate a stem cell when the laboratory of Dr. Irving Weissman reported the prospective identification of mouse hematopoietic stem cells in 1986. In 2008, flow cytometry still sets the standard for cell enrichment. Thus, a state of the art flow cytometry core is critical for the isolation of solid tumor and leukemia stem cells for the 3 projects of this proposal. When working with human specimens obtained from the pathologist, one cannot predict with certainty when a specimen will arrive. This is predominantly because of the inherent uncertainty of surgical scheduling and issues that arise during an operation. The successful isolation of cancer stem cells is dependent upon the speed in which a tumor or blood sample is processed and sorted. Thus, one must be able to access a flow cytometer quickly for studies involving human tumor cells. This ensures that each tumor sample is analyzed in a timely and efficient manner, and data from each precious sample is not compromised by delays in processing because of lack of access to a flow cytometer. This is one of many reasons why the Stanford University Stem Cell Institute has established a flow cytometry core for the use of investigators in the Institute. Although commercial flow cytometers are quite sophisticated, they need to be modified for optimal isolation of cells from different tissues. In addition, each of the flow cytometers in this core has been modified so that both hematopoeitic and solid tissue stem cells can be isolated using optimal conditions. This is made possible in part by the core leader, David Parks. Based on Institute user's needs, the flow cytometers receive customized factory components. In addition, factory settings have been modified by the core PI to optimize sorting efficiency of both blood and solid tissue stem cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Lee, Cleo Yi-Fang; Lin, Yuan; Bratman, Scott V et al. (2014) Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res 74:341-52
Wang, Jianbin; Quake, Stephen R (2014) RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 111:13157-62
Wu, Angela R; Neff, Norma F; Kalisky, Tomer et al. (2014) Quantitative assessment of single-cell RNA-sequencing methods. Nat Methods 11:41-6
Pan, Ying; Volkmer, Jens-Peter; Mach, Kathleen E et al. (2014) Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Sci Transl Med 6:260ra148
Isobe, Taichi; Hisamori, Shigeo; Hogan, Daniel J et al. (2014) miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife 3:
Edris, Badreddin; Willingham, Stephen B; Weiskopf, Kipp et al. (2013) Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A 110:3501-6
Tseng, Diane; Volkmer, Jens-Peter; Willingham, Stephen B et al. (2013) Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110:11103-8
Pang, Wendy W; Pluvinage, John V; Price, Elizabeth A et al. (2013) Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 110:3011-6
Weiskopf, Kipp; Ring, Aaron M; Ho, Chia Chi M et al. (2013) Engineered SIRP* variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88-91
Bockhorn, Jessica; Yee, Kathy; Chang, Ya-Fang et al. (2013) MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 137:373-82

Showing the most recent 10 out of 21 publications